Trials

RFR-CABG

The RFR-CABG trial aims to compare RFR guided versus angiography guided CABG revascularization and to define the best cut-off value that predicts graft occlusion for RFR.

The RFR-CABG trial is an international prospective randomized multicenter superiority trial designed to enroll 500 patients in Belgium and Poland.

DUTCH CANGRELOR REGISTRY

The Dutch Cangrelor Registry aims to investigate the efficacy and safety of cangrelor in the Netherlands.

The Dutch Cangrelor Registry is a multicenter non-interventional prospective registry aiming to include 250 patients in 8 centres in The Netherlands.

ECTOPIA

The ECTOPIA trial aims to compare the efficacy of AAD (flecainide/verapamil and sotalol) and catheter ablation in reducing VPB burden after 3 months in patients with frequent symptomatic idiopathic VPB/VT.

The ECTOPIA trial is a national, multicenter, prospective, randomized clinical trial designed to enroll 180 patients in up to 6 centers in The Netherlands.

COLOR

The COLOR trial aims to investigate whether transradial PCI is associated with less access site related bleeding- and/or vascular complications as compared with transfemoral PCI for complex coronary lesions with large-bore 7 Fr guiding catheters.

The trial is an international, multicenter, prospective, randomized clinical trial designed to enroll 388 patients in up to 12 centers in Europe (The Netherlands, Belgium, Germany, United Kingdom and Switzerland).

DETECT AF

DETECT AF aims to examine the feasibility of screening persons of ≥65 years old for AAF and to validate the smartphone connected MED as an AAF screening instrument for application in transmural care in the Netherlands.

The DETECT AF project is a national prospective study designed to enroll 4000 patients in The Netherlands.

TCW

The TCW trial aims to investigate whether FFR-guided PCI and TAVI strategy for treatment of MVD and AS will be non-inferior to CABG and SAVR for a composite primary endpoint of all-cause mortality, stroke, myocardial infarction, coronary or valve re-intervention and life-threatening or disabling bleeding at one year.

The trial is a prospective, randomized, controlled, open label, multicenter, international, non-inferiority trial designed to enrol 328 patients in up to 22 centers in Europe (The Netherlands, Belgium, Germany, Denmark, Hungary, Spain, Greece, Austria and Portugal).

CIPA

The purpose of the CIPA Trial is to compare the efficacy and safety of complex fractionated atrial electrocardiograms (CFAEs) guided ablation to pulmonary vein isolation (PVI) based ablation in patients with persistent atrial fibrillation (AF).

The CIPA trial is an international (The Netherlands, France and Japan), multicenter, prospective, randomized, unblinded, clinical trial designed to enrol 120 patients.

EU-CaRE RCT (e-Health)

The aim of EU-CaRE is to improve quality of life and independency of elderly coronary patients (≥ 65 years old). A network of leading European experts from seven countries (The Netherlands, Denmark, Italy, Spain, Switzerland, Germany, Belgium and France) and 8 institutes have started this project in order to compare, improve and tailor cardiac rehabilitation programmes for these patients (EU-CaRE trial). In addition, the e-technology will be tested in a randomized control study (EU-CaRE RCT trial).

The trial is designed to enrol 238 patients in total.

EU-CaRE

The aim of EU-CaRE trial is to improve quality of life and independency of elderly coronary patients (≥ 65 years old). A network of leading European experts from seven countries (The Netherlands, Denmark, Spain, Switzerland, Italy, Germany and France) and 8 institutes have started this project in order to compare, improve and tailor cardiac rehabilitation programmes for these patients (EU-CaRE trial).

The trial is designed to enrol 1760 patients.

REDUCE

The REDUCE trial is designed to evaluate the potential for shorter-term dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients treated with the COMBO Dual Therapy Stent.

The physician-initiated, prospective, multicenter, randomized trial has now completed enrolment of all 1500 patients in 36 centers in Asia (Hong Kong, Singapore, Malaysia and Indonesia) and Europe (The Netherlands, Italy, Belgium, Germany, Poland and Hungary).